Is serum galectin-3 a potential predictor of the response to active specific immunotherapy in melanoma patients? [23]

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 2, 2007, Pages 278-280

  Vereecken, Pierre ^a,b   Heenen, Michel ^a   Babar, Sajida ^a   Van Baren, Nicolas ^a  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b NONE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 3; MELANOMA VACCINE; RECOMBINANT MELANOMA ANTIGEN 3; RECOMBINANT VACCINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LETTER; MELANOMA; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANK SUM TEST;

ENZYME-LINKED IMMUNOSORBENT ASSAY; GALECTIN 3; HUMANS; IMMUNOTHERAPY, ACTIVE; MELANOMA; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 33846383430     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01853.x     Document Type: Letter

References (9)

1. May A, Berthier-Vergnes O, Apoil PA et al. Expression of the galactose binding protein Mac-2 by human melanoma cell lines. Cancer Lett 1994; 81: 155-163.
2. Iurisci I, Tinari N, Natoli C et al. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000; 6: 1389-1393.
3. Vereecken P, Debray C, Petein M et al. Expression of galectin-3 in primary and metastatic melanoma: Immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch Dermatol Res 2005; 296: 353-358.
4. Vereecken P, Zouaoui Boudjeltia K, Debray C et al. High serum galectin-3 in advanced melanoma: Preliminary results. Clin Exp Dermatol 2006; 31: 105-109.
5. Califice S, Castronovo V, Van Den Brule F. Galectin-3 and cancer (Review). Int J Oncol 2004; 25: 983-992.
6. Rubinstein N, Alvarez M, Zwirner NW et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5: 241-251.
7. Almkvist J, Karlsson A. Galectins as inflammatory mediators. Glycoconj J 2004; 19: 575-581.
8. Fukumori T, Takenaka Y, Oka N et al. Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 2004; 64: 3376-3379.
9. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.